Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

Journal of Clinical Oncology

Volumn 26, Issue 33, 2008, Pages 5352-5359

  Heinrich, Michael C ^a   Maki, Robert G ^a   Corless, Christopher L ^a   Antonescu, Cristina R ^a   Harlow, Amy ^a   Griffith, Diana ^a   Town, Ajia ^a   McKinley, Arin ^a   Ou, Wen Bin ^a   Fletcher, Jonathan A ^a   Fletcher, Christopher D M ^a   Huang, Xin ^a   Cohen, Darrel P ^a   Baum, Charles M ^a   Demetri, George D ^a  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SUNITINIB;

ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG RESPONSE; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; KIT GENE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PDGFRA GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ADULT; AGED; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; EXONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENOTYPE; HUMANS; INDOLES; MALE; MIDDLE AGED; MUTATION; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; PYRROLES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 56749098278     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.7461     Document Type: Article

References (39)

1. Corless CL, Schroeder A, Griffith D, et al: PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23:5357-5364, 2005
2. Heinrich MC, Corless CL, Duensing A, et al: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710, 2003
3. Debiec-Rychter M, Sciot R, Le Cesne A, et al: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093-1103, 2006
4. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
5. Verweij J, Casali PG, Zalcberg J, et al: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364:1127-1134, 2004
6. Van Glabbeke M, Verweij J, Casali PG, et al: Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 23:5795-5804, 2005
7. O'Farrell AM, Abrams TJ, Yuen HA, et al: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605, 2003
8. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
9. Abrams TJ, Lee LB, Murray LJ, et al: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small-cell lung cancer. Mol Cancer Ther 2:471-478, 2003
10. Murray LJ, Abrams TJ, Long KR, et al: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757-766, 2003
11. Kim DW, Jo YS, Jung HS, et al: An orally administered multi-target tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070-4076, 2006
12. Maki RG, Fletcher JA, Heinrich MC, et al: Results from a continuation trial of SU11248 in patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol 23:818s, 2005 (suppl; abstr 9011)
13. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006
14. Heinrich MC, Corless CL, Demetri GD, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349, 2003
15. Debiec-Rychter M, Dumez H, Judson I, et al: Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40:689-695, 2004
16. Antonescu CR, Besmer P, Guo T, et al: Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11:4182-4190, 2005
17. Heinrich MC, Corless CL, Blanke CD, et al: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24:4764-4774, 2006
18. Bertucci F, Goncalves A, Monges G, et al: Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour. Oncol Rep 16:97-101, 2006
19. Loughrey MB, Beshay V, Dobrovic A, et al: Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones. Histopathology 49:99-100, 2006
20. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al: Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12:1743-1749, 2006
21. Grimpen F, Yip D, McArthur G, et al: Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour. Lancet Oncol 6:724-727, 2005
22. Tamborini E, Gabanti E, Lagonigro MS, et al: KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient. Cancer Res 65:1115, 2005
23. McLean SR, Gana-Weisz M, Hartzoulakis B, et al: Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. Mol Cancer Ther 4:2008-2015, 2005
24. Debiec-Rychter M, Cools J, Dumez H, et al: Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128:270-279, 2005
25. Wardelmann E, Thomas N, Merkelbach-Bruse S, et al: Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 6:249-251, 2005
26. Chen LL, Trent JC, Wu EF, et al: A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64:5913-5919, 2004
27. Tamborini E, Bonadiman L, Greco A, et al: A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127:294-299, 2004
28. Wakai T, Kanda T, Hirota S, et al: Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. Br J Cancer 90:2059-2061, 2004
29. Prenen H, Cools J, Mentens N, et al: Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12:2622-2627, 2006
30. Carter TA, Wodicka LM, Shah NP, et al: Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 102:11011-11016, 2005
31. Tuveson DA, Willis NA, Jacks T, et al: STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications. Oncogene 20:5054-5058, 2001
32. Noma K, Naomoto Y, Gunduz M, et al: Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines. Oncol Rep 14:645-650, 2005
33. Heinrich MC, Maki RG, Corless CL, et al: Sunitinib response in imatinib-resistant GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol 24:520s, 2006 (suppl; abstr 9502)
34. Yuzawa S, Opatowsky Y, Zhang Z, et al: Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 130:323-334, 2007
35. Dibb NJ, Dilworth SM, Mol CD: Switching on kinases: Oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer 4:718-727, 2004
36. Guo T, Agaram NP, Wong GC, et al: Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 13:4874-4881, 2007
37. Potapova O, Laird AD, Nannini MA, et al: Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 5:1280-1289, 2006
38. Erber R, Thurnher A, Katsen AD, et al: Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J 18:338-340, 2004
39. Bergers G, Song S, Meyer-Morse N, et al: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295, 2003